Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amira Pharmaceuticals, Inc.

http://www.amirapharm.com/index.htm

Latest From Amira Pharmaceuticals, Inc.

Natural Beauty Big Leaguer L’Occitane Acquires No. 1 In British Luxury Skin Care

L’Occitaine’s $900m Elemis buy will build out the manufacturer/retailer’s premium, natural-oriented beauty portfolio, adding a prestige brand that aspires to be a leader in global skin care with its nature/science balance and cross-generational consumer appeal.

Beauty Deals

Vitamin Shoppe CEO Has Executive Experience In Cosmetics And Food Sectors

Sharon Leite has been Godiva Chocolatier president in North America since October 2017 will begin as Vitamin Shoppe CEO on Aug. 27. The firm agreed to part ways with former CEO Colin Watts in February after it reported 2017 net sales down 8.5% to $1.2bn for a net loss of $252.2m and $10.90 per share.

Advertising, Marketing & Sales Business Strategies

Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership

Hanmi is reviewing a new global clinical trial plan for its novel lung cancer drug olmutinib after China's ZAI Lab returned its rights, and following Boehringers cancellation of a major-licensing deal in 2016. ZAI's decision may reflect the difficulties faced by olmutinib and other third generation EGFR inhibitors in competing with Tagrisso, as well as the increasingly crowded and rapidly changing non-small cell lung cancer space.

Commercial Deals

From Inception, Tempest Plans To Kick Up IO Storm

Emerging Company Profile: Spinning out of Versant Ventures’ Inception Sciences, San-Francisco-based development-stage biotech Tempest Therapeutics Inc. completes $70m Series B round to advance small molecules that modulate anti-tumor immunity pathways.

Financing StartUps and SMEs
See All

Company Information

UsernamePublicRestriction

Register